ISRCTN63718248已完成3 期
A phase III, randomised, double blind, multicentre study to evaluate the safety and efficacy of dalbavancin versus linezolid in the treatment of complicated skin and soft tissue infections with suspected gram-positive bacterial pathogens
试验速览
- 阶段
- 3 期
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Patients having infection consistent with complicated skin and soft tissue infection either involving deeper soft tissue or requiring significant surgical intervention
- •2. Patients to require 24hrs of parental therapy for suspected gram-positive complicated skin
排除标准
- •Not provided at time of registration
研究者
相似试验
进行中（未招募）
1 期
A phase III, randomised, double-blind, multicentre study comparing the efficacy, safety, and immunogenicity of proposed tocilizumab biosimilar (DRL_Tocilizumab) with tocilizumab reference product (RoActemra®) administered by the subcutaneous route as an add-on to methotrexate in the treatment of patients with moderate to severe rheumatoid arthritisAdult patients of either gender with active moderate to severe rheumatoid arthritis (1987 revised ACR criteriaArnett et al. 1987) of at least 6 months duration, with an inadequate response to cDMARDs and currently on treatment with stable doses of MTX for at least 8 weeks prior to randomisation will be eligible for the study. Up to 25% of patients might have also been previously exposed to bDMARDs.Patients with previous exposure to other cDMARD and bDMARD would enter the study after an adequate washout period.Patients previously exposed to JAK pathway inhibitors will not be allowed in the study.MedDRA version: 21.0Level: PTClassification code: 10039073Term: Rheumatoid arthritis Class: 100000004859MedDRA version: 21.1Level: LLTClassification code: 10039074Term: Rheumatoid arthritis aggravated Class: 10028395MedDRA version: 21.1Level: LLTClassification code: 10066578Term: Progression of rheumatoid arthritis Class: 10028395MedDRA version: 20.0Level: HLTClassification code: 10039075Term: Rheumatoid arthritis and associated conditions Class: 10021428CTIS2022-501361-44-00Dr. Reddy's Laboratories Limited448
已完成
3 期
A phase III, randomised, double-blind, multicentre, parallel-group, placebo- and active-controlled, dose-optimisation safety and efficacy study of Lisdexamfetamine Dimesylate (LDX) in children and adolescents aged 6-17 with attention-deficit/hyperactivity disorder (ADHD)ADDHyperactivity10009841NL-OMON31918PRA International50
已完成
3 期
A Phase III, randomised, double-blind, multicentre, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of dolutegravir plus lamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected treatment-naïve adultsHIV-infectionHlV-1 infectionHuman lmmunodeficiency Virus-1 lnfectionNL-OMON50555ViiV Healthcare UK Limited18
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and tolerability of dolutegravir pluslamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not been treated yet.Human Immunodeficiency Virus-1 infectionMedDRA version: 20.1Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-000459-28-DEViiV Healthcare UK Limited722
进行中（未招募）
1 期
A study to evaluate the efficacy, safety, and tolerability of dolutegravir pluslamivudine compared to dolutegravir plus tenofovir/emtricitabine in HIV-1-infected patients that have not been treated yet.Human Immunodeficiency Virus-1 infectionMedDRA version: 19.0Level: LLTClassification code 10068341Term: HIV-1 infectionSystem Organ Class: 100000004862EUCTR2016-000459-28-ESViiV Healthcare UK Limited722